This year's late-breaking HIV science has been added to the online programme for the 9th IAS Conference on HIV Science (IAS 2017). Take a look at the full programme, now updated with all accepted abstracts, satellite symposia and more. New scientific highlights include:
- Findings on safety, tolerability and pharmacokinetics of long-acting, injectable pre-exposure prophylaxis (PrEP)
- Interim data on the efficacy of a dolutegravir-based regimen as a second-line treatment in a resource-limited setting
- Clinical trial findings on the impact of a broadly neutralizing antibody on time to viral rebound
- Final results from the Opposites Attract study on treatment as prevention for male serodiscordant couples
- Clinical update on a perinatally infected child following prolonged cessation of antiretroviral treatment
- Interim results on the feasibility, safety and efficacy of direct-acting antivirals to treat hepatitis C in sub-Saharan Africa
- Results from a trial of a shorter and more sustainable treatment regimen for HIV-associated meningitis
- First evidence of the impact of scaling up treatment and prevention in the country with the highest HIV rates in the world
- New estimates of the clinical and economic impacts of integrating HIV treatment into maternal and child health services
Visit the IAS 2017 online programme to browse all sessions, mark your favourites, and build your own custom itinerary.